Morgan Stanley upgraded Kymera Therapeutics, Inc. (NASDAQ:KYMR) to "Overweight" with a price target raised to $73.Kymera reported a quarterly loss of $0.90 per share, missing the Zacks Consensus Estimate by 26.76%.The company's revenue for Q3 2025 was $2.76 million, falling short of expectations by 89.6%.Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a biopharmaceutical company focused on developing novel protein degradation therapies. Operating in the Zacks Medical - Biomedical and Genetics industry, Kymera ai ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Kymera Therapeutics (NasdaqGM:KYMR) Q3 2025 Earnings Call November 04, 2025 08:30 AM ET Speaker3Good day, everyone. My name is Sophie, and I will be your conference operator today. At this time, I would like to welcome you to the Kymera Therapeutics third quarter 2025 results call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. If you would like to ask a question during this time, and you have joined via the webin ...

Kymera Therapeutics (NasdaqGM:KYMR) Q3 2025 Earnings Call November 04, 2025 08:30 AM ET Speaker0Good day, everyone. My name is Sophie, and I will be your conference operator today. At this time, I would like to welcome you to the Chimera Therapeutics third quarter twenty twenty five results call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session.If you would like to ask a question during this time and you have joined ...

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to a loss of $0.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -26.76%. A quarter ago, it was expected that this company would post a loss of $0.83 per share when it actually produced a loss of $0.95, delivering a surprise of -14.46%.Over the last four quarters, the company ...

Kymera Therapeutics Third Quarter 2025 Quarterly Results Call November 4, 2025 Agenda Introduction Justine Koenigsberg, Vice President, Investor Relations Key Highlights and Business Update Nello Mainolfi, PhD, Founder, President and Chief Executive Officer Clinical Update Jared Gollob, MD, Chief Medical Officer Financial Review Bruce Jacobs, CFA, MBA, Chief Financial Officer Question and Answer Session Forward Looking Statements This presentation contains forward-looking statements within the meaning of th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...

Financial Performance - Kymera Therapeutics reported collaboration revenues of $2.8 million for Q3 2025, down from $3.7 million in Q3 2024, all attributable to collaboration with Gilead Sciences[8] - The net loss for Q3 2025 was $82.2 million, compared to a net loss of $62.5 million in Q3 2024[12] - Net loss attributable to common stockholders for Q3 2025 was $82,175,000, compared to a net loss of $62,487,000 in Q3 2024, representing a 31.5% increase in losses[19] - Net loss per share attributable to common stockholders was $0.94 for Q3 2025, compared to $0.82 for Q3 2024[19] - Total operating expenses for Q3 2025 were $95,285,000, an increase of 25.5% from $75,865,000 in Q3 2024[19] - For the nine months ended September 30, 2025, total operating expenses were $287,844,000, up 30.5% from $220,558,000 in the same period of 2024[19] - Total other income for Q3 2025 was $10,346,000, an increase from $9,637,000 in Q3 2024[19] Research and Development - Research and development expenses increased to $74.1 million in Q3 2025 from $60.4 million in Q3 2024, primarily due to investments in the STAT6 program and growth in the R&D organization[10] - The KT-621 BroADen Phase 1b trial in atopic dermatitis has completed enrollment and dosing, with data expected in December 2025[1] - The KT-621 BROADEN2 Phase 2b trial in atopic dermatitis has been initiated, with topline data expected by mid-2027, involving approximately 200 patients[4] - The KT-579 IND-enabling studies have been completed, with a Phase 1 clinical trial expected to start in early 2026[1] - The company is on track to initiate the BREADTH Phase 2b trial in asthma patients in Q1 2026, which is expected to accelerate KT-621 development[4] Expenses - General and administrative expenses rose to $17.3 million in Q3 2025 compared to $15.5 million in Q3 2024, driven by increased legal and professional service fees[11] - General and administrative expenses rose to $17,336,000 in Q3 2025, compared to $15,455,000 in Q3 2024, reflecting a 12.1% increase[19] - Impairment of long-lived assets was recorded at $3,855,000 in Q3 2025, while there was no impairment in Q3 2024[19] Leadership Changes - Kymera appointed Brian Adams as Chief Legal Officer and Corporate Secretary in September 2025 to lead legal and corporate governance functions[7] Cash Position - As of September 30, 2025, Kymera had $978.7 million in cash and cash equivalents, providing a runway into the second half of 2028[12] Stock Information - The weighted average common stocks outstanding for Q3 2025 was 87,300,286, compared to 76,125,975 in Q3 2024[19]

Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025 Initiated KT-621 BROADEN2 Phase 2b trial in AD KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 KT-579 (IRF5) IND-enabling studies completed, with Phase 1 clinical trial expected to start in early 2026 Well-capitalized with $979 million in cash as of September 30, 2025, and runway into the second half of 2028 Company to hold video confere ...

WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2025 financial results on November 4, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investo ...